Universitat de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

  2. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457

  3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  4. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Journal of Hepatology

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  2. Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial

    Journal of Clinical Oncology

  3. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    ESMO Open, Vol. 8, Núm. 3

2022

  1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  2. Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)

    Annals of Oncology

  3. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  4. Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission

    Medicina Clinica

  5. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

  6. Reply to: “An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously”

    Journal of Hepatology

  7. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  3. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  4. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  5. Systemic treatment of hepatocellular carcinoma: An EASL position paper

    Journal of Hepatology, Vol. 75, Núm. 4, pp. 960-974

2020

  1. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

    Journal of Hepatology, Vol. 72, Núm. 2, pp. 320-341